Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2022 call → NO1. The user asks to determine if management explains the company's business direction by narrating what its counterparties are themselves doing and scaling, based solely on the provided earnings call transcript. 2. I need to analyze the transcript for the three key conditions: * (1) Management speaks about counterparties' business as part of its own, with real substance on their ramps/launches/adoption. * (2) The company is already inside that growth (current revenue flowing), not just bidding. * (3) The counterparties' trajectory is early and large relative to the company. 3. Let's scan the transcript for mentions of counterparties (customers, partners, payers, etc.) and their trajectories. 4. Key counterparties mentioned: * Genentech (partner in drug discovery/cell therapy). Management discusses progress on two cell therapy programs, IND filing, and milestones. However, the discussion is about *their* progress on a shared program, and the company is already in it (revenue from amortization). But is the forward account *driven* by Genentech's own scaling? The IND acceptance is a milestone, but the narrative is more about the company's own drug discovery efforts and the partner's decision-making. The Genentech amortization is actually a headwind (decreasing). The IND filing is a milestone, not a scaling of Genentech's own operations that the company supplies. * Pharma services customers (biopharma customers). Management says "pharma services had substantial growth of 67% versus 2021" and "we deliver rich and valuable immune receptor data to our biopharma customers". But does management narrate *their* ramps, launches, or scaling? No, it just says "increase penetration with our portfolio pharma companies" and "head down, focused on doing that to generate revenue guidance." This is about the company's own selling effort, not the counterparties' own trajectories. * MRD pharma partnerships (e.g., multiple myeloma therapy approval). They recognized a $2 million milestone from the approval of another therapy. This is a milestone, not a scaling narrative of the partner's own business. * Payers (private payers, Medicaid plans). Management discusses ASP growth and getting pricing agreements. This is about the company's own pricing/collection efforts, not the payers' own scaling. * Community practices (large accounts).
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.